A GLOBAL COLLABORATION
In 2013 collaborate efforts began to bring together the world’s preeminent GBM-battling scientists and institutions. Over the course of the next two years, the vision took form, bolstered by U.S. Vice President Joseph Biden, whose high-profile call to action following his son Beau’s spring 2015 death resulting from GBM particularly galvanized the brain cancer community.
At a November 13, 2015, event in Washington, D.C. attended by Vice President Biden, the GBM AGILE program was formally launched. The initiative was overseen for its first two years by the National Biomarker Development Alliance, which developed the initial draft of the GBM AGILE adaptive clinical trial master protocol. In late 2017, GBM AGILE’s sponsorship and management were transferred to the Global Coalition for Adaptive Research (GCAR), where it remains and under whose sponsorship the platform has grown and developed. Today, the GBM AGILE coalition represents a dedicated group of world-class—and world-stretching—neurosurgeons, neuro-oncologists, basic and clinical investigators, cancer advocacy and oncology research funding community members. It’s core is comprised of some 150 researchers from more than 40 leading institutions across four continents. The globally collaborative effort of GBM AGILE is accelerating the pace of discovery.
GLOBAL COALITION FOR ADAPTIVE RESEARCH
The Global Coalition for Adaptive Research is a 501(c)(3) non-profit established in 2017 to speed the discovery and development of cures for patients with deadly diseases. The sponsorship and operationalization of GBM AGILE into a self-sustaining engine of therapeutic and biomarker development for brain cancer patients is its first priority. As the adaptive clinical trial initiative’s sponsor, GCAR conducts GBM AGILE’s overall management of the trial, including regulatory oversight, safety monitoring, clinical management, pipeline building, partnership engagement and financial responsibility.